A recent study advances the understanding of factors associated with a target serum urate level of 6 mg/dL or less. Researchers found such factors as having a rheumatologist as the main provider of gout care contributed to achieving and maintaining this outcome. However, the presence of co-morbidities lowered a patient’s chances for achieving the target serum urate level, even with allopurinol use…
A farewell message from outgoing Government Affairs Committee Chair Angus Worthing urges ACR/ARP members to advocate for the rheumatology profession.
With multiple healthcare policy issues currently in play, Dr. Solow believes making rheumatologists’ voices heard is crucial to the specialty’s success.
Dr. Poole’s cited priorities include building an interprofessional membership team through developing resources and promoting rheumatology to health professionals in many disciplines.
(Reuters)—U.S. President Donald Trump has nominated Stephen Hahn, MD, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the U.S. Food and Drug Administration (FDA), the White House said on Friday. Dr. Hahn, a radiation oncologist who has been at MD Anderson in Houston since 2015, if confirmed would follow…
New research seeking to describe the characteristics of undefined, systemic autoinflammatory diseases may have identified distinct subgroups, including pericarditis and intellectual impairment…
A recent study has taken a more detailed look at the relationship between physical activity and the risk of developing rheumatoid arthritis (RA). Researchers found the more patients exercised weekly the lower their overall risk, specifically brisk and very brisk walking paces, along with longer cumulative average walking hours weekly were associated with a reduced risk for RA…
Crafting clear and captivating messaging for patients and colleagues isn’t always easy. Here are some tips to improve your approach…
This study used up-to-date techniques to perform an exhaustive immunologic description of cryoglobulins with regard to characterization and quantification…
NEW YORK (Reuters Health)—Iguratimod, a disease-modifying drug marketed in China and Japan, appears to be effective in treating rheumatoid arthritis (RA) and possibly other autoimmune diseases, while protecting against adverse bone effects, researchers from China say. Iguratimod is a methane sulfonanilide compound that influences several anti-inflammatory and immune-modulatory pathways and has an anabolic effect on…